



(51) International Patent Classification:

C12M 1/34 (2006.01)

G01N 33/53 (2006.01)

C12Q 1/00 (2006.01)

G01N 33/543 (2006.01)

B01L 3/00 (2006.01)

(21) International Application Number:

PCT/US2019/015579

(22) International Filing Date:

29 January 2019 (29.01.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/623,038 29 January 2018 (29.01.2018) US

62/676,079 24 May 2018 (24.05.2018) US

62/703,702 26 July 2018 (26.07.2018) US

(71) Applicant: RITE TASTE, LLC [US/US]; 80 Westcliff Road, Weston, MA 02493 (US).

(72) Inventor; and

(71) Applicant: NAWANA, Namal [US/US]; 33 Westcliff Road, Weston, MA 02493 (US).

(72) Inventors: FOTOUHI, Mohammed; 80 Westcliff Road, Weston, MA 02493 (US). TASLIM, Mohammed E.; 46 Cedar Springs Lane, Needham, MA 02492 (US).

ABEDI, Mehdi; 2 Larose Place, Apt. 3, Brighton, MA 02135 (US). GREENFIELD, Edward Alvin; 160 Poskus Street, Stoughton, MA 02072 (US). MOLLAAGHABA-BA, Reza; 17 Brook Street, Natick, MA 01760 (US).


(74) Agent: ROLLER, Derek et al.; Nutter McClennen & Fish LLP, Seaport West, 155 Seaport Boulevard, Boston, MA 02210-2604 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: METHODS AND DEVICES FOR DETECTION OF PATHOGENS

FIG. 1A



(57) Abstract: A method of detecting a pathogen, e.g., listeria bacterium, chlamydia bacteria, gonorrhea bacteria and/or HPV, in a sample is disclosed, which comprises bringing a sample into contact with a graphene layer functionalized with an antibody exhibiting specific binding to the pathogen, monitoring electrical resistance of said antibody functionalized graphene layer in response to interaction with said sample, and detecting presence of the pathogen in said sample by detecting a change in said electrical resistance indicative of interaction of the pathogen with said antibody-functionalized graphene layer. For example, a decrease of the electrical resistance of the graphene layer can indicate the presence of the pathogen in the sample under study. In some embodiments, a method according to the present teachings is capable of detecting pathogens, such as listeria bacteria, chlamydia bacteria, gonorrhea bacteria and HPV in a sample at a concentration as low as 4cfu per 100 grams of a sample.

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*

METHODS AND DEVICES FOR DETECTION OF PATHOGENS

Cross-Reference to Related Applications

This application claims the benefit of U.S. Provisional Application No. 62/623,038, entitled “Methods and Devices for Detection for *Listeria Monocytogenes* Bacterium,” and filed on January 29, 2018. This application also claims the benefit of U.S. Provisional Application No. 62/676,079, entitled “A Graphene Functionalized Sensor,” and filed on May 24, 2018. This application also claims the benefit of U.S. Provisional Application No. 62/703,702, entitled “Methods and Devices for Detection of Pathogens,” and filed on July 26, 2018. The entire contents of these applications are incorporated by reference herein.

Background

The present invention relates generally to methods and devices for the detection of pathogens, such as bacteria and viruses, in a sample, e.g., a food sample.

Pathogens can cause a variety of diseases and can infect subjects through a myriad of modalities, e.g., food supply or contact with an infected individual. By way of example, *listeria monocytogenes* is a Gram-positive pathogenic bacterium that causes the infection listeriosis. It is a facultative anaerobic bacterium, which is capable of surviving in the presence or absence of oxygen. It is one of the most virulent foodborne pathogens and can lead to fatality, especially in vulnerable populations. Its ability to grow at typical refrigeration temperatures greatly enhances its ability to evade control in human foodstuffs. Conventional methods for detecting *listeria* in food samples can be time-consuming and cumbersome. Similar problems are presented in detection of other pathogens, such as *chlamydia* and *gonorrhea*.

Chlamydia is a genus of pathogenic bacteria that are obligate intracellular parasites. For example, *Chlamydia trachomatis* (*C. trachomatis*) is responsible for causing blindness of millions of infected patients worldwide. *Gonorrhea* is a sexually transmitted infection (STI) caused by the bacterium *Neisseria gonorrhoeae*. Other pathogenic agents, such as viruses, can also cause a variety of diseases. For example, human papillomavirus infection is an infection caused by human papillomavirus (HPV). In some patients, an HPV infection can result in warts or precancerous lesions.

Accordingly, there is a need for improved methods and systems for detecting pathogenic agents.

Summary

In one aspect, a method of detecting a pathogen, e.g., listeria bacterium, chlamydia bacteria, gonorrhea bacteria and/or HPV, in a sample is disclosed, which comprises bringing a sample into contact with a graphene layer functionalized with an antibody exhibiting specific binding affinity to the pathogen, monitoring electrical resistance of said antibody-functionalized graphene layer in response to interaction with said sample, and detecting presence of the pathogen in said sample by detecting a change in said electrical resistance indicative of interaction of the pathogen with said antibody-functionalized graphene layer. By way of example, a change in the electrical resistance of the antibody-functionalized graphene layer that exceeds a predefined threshold can indicate the presence of a pathogen of interest in a sample under study. For example, a decrease of the electrical resistance of the graphene layer can indicate the presence of the pathogen in the sample under study. In some embodiments, a temporal pattern of change in the resistance of the underlying antibody-functionalized graphene layer in response to its exposure to a sample under study can be correlated with the presence of a particular pathogen in the sample under study. By way of example, in some such embodiments, the detected temporal pattern of change in the resistance of the underlying antibody-functionalized graphene layer can be compared with a calibration pattern to determine whether a pathogen of interest is present in the sample under study.

In some embodiments, a method according to the present teachings is capable of detecting pathogens, such as listeria bacteria, chlamydia bacteria, gonorrhea bacteria and HPV in a sample at a concentration as low as 4 cfu (colony forming units) per 100 grams of a sample.

In some embodiments, the graphene layer is incorporated in a device that comprises a substrate, e.g., a glass or a semiconductor substrate, on which the graphene layer is disposed. A pair of electrically conductive pads can be in electrical contact with the graphene layer to facilitate the measurement of the electrical resistance of the graphene layer in response to interaction with a sample under study. In some embodiments, such a device can include a microfluidic structure that is coupled to said semiconductor substrate, where the microfluidic

structure has at least one reservoir and a fluidic channel fluidly coupled to the reservoir. The fluid channel can be in fluid communication with at least a portion of the graphene layer, and the reservoir can be configured for receiving a sample.

In a related aspect, a sensor for detecting a pathogen in a sample is disclosed, which comprises a substrate, a graphene layer deposited on a surface of the substrate, where the graphene layer is functionalized with a plurality of antibodies exhibiting specific binding affinity to the pathogen. A reference electrode is disposed in proximity of the antibody-functionalized graphene layer. The sensor can further comprise a microfluidic delivery device coupled to the functionalized graphene layer for delivery of a fluid sample thereto. In some embodiments, the microfluidic device can comprise two fluid reservoirs and a fluid channel connecting said two reservoirs. An AC voltage source can be utilized to apply an AC voltage to the reference electrode to facilitate the detection of a change in at least one electrical property of the antibody-functionalized graphene layer, e.g., its DC resistance, in response to the interaction of the pathogen with that layer. By way of example, the applied AC voltage can have a frequency in a range of about 1 kHz to about 1 MHz and an amplitude in a range of about 1 millivolt to about 3 volts.

In a related aspect, a system for detecting pathogenic agents in a sample is disclosed, which comprises a sensor configured for detecting at least two pathogenic agents. The system comprises a substrate, and a plurality of sensing units disposed on said substrate, where each of said sensing units comprises an antibody-functionalized graphene layer disposed on said substrate. At least two of said sensing units comprise antibodies configured for specific binding to at least two different pathogens.

In some embodiments, the above system includes at least one reference electrode for application of an AC signal to at least one of the sensing units. In some such embodiments, a plurality of reference electrodes are provided, each of which is configured for application of an AC signal to one of the sensing units. By way of example, the AC signal can have a frequency in a range of about 1 kHz to about 1 MHz and an amplitude in a range of about 1 millivolt to about 3 volts.

In some embodiments, the system can further include a device for measuring the resistance of the underlying graphene layer for detecting a change, if any, in the resistance of the underlying graphene layer in response to its exposure to a sample under investigation. By

way of example, the system can include at least one voltage measuring device for measuring a voltage developed across one or more of said sensing units in response to application of a predefined current thereto. An analyzer in communication with the voltage measuring device can receive the measured voltage and utilize the measured voltage together with the predefined current applied to a sensing unit to determine the resistance of the graphene layer associated with that sensing unit. The analyzer can further determine whether the calculated resistance of the sensing unit is indicative of the presence of a pathogen of interest in a sample that was brought into contact with the sensing unit, for example, in a manner discussed above.

In some embodiments, a multiplexer can be disposed between the voltage measuring device and the sensing units to allow sequential measurement of the voltages developed across the sensing units of the sensor in response to application of a predefined current thereto.

In some embodiments, a sensor according to the present teachings includes a plurality of sensing units, each of which is functionalized with a different antibody exhibiting specific binding affinity to a different pathogen. A microfluidic device is coupled to the sensing units for dividing a sample among the sensing units. The microfluidic device can include an input port for receiving a fluid sample, an input manifold for dividing the sample among a plurality of channels each of which is in communication with one of the sensing units. A return manifold can receive the fluid exiting the sensing units and can return the fluid to the input manifold to provide a closed-loop circulation path. In some cases, rather than utilizing a single return path, each sensing unit can include its dedicated fluid return path. In some embodiments, one or more pumps can be employed to facilitate the circulation of the sample through the microfluidic channels.

Further understanding of various aspects of the invention can be obtained by reference to the following detailed description in conjunction with the associated drawings, which are briefly described below.

Brief Description of the Drawings

FIG. 1A is a schematic top view of a sensor system according to an embodiment of the present teachings for detecting a pathogen in a sample,

FIG. 1B is a schematic cross-sectional view of the system depicted in FIG. 1A,

FIG. 2 is a schematic depiction of an antibody-functionalized graphene layer employed in a device according to the present teachings,

FIG. 3 schematically depicts a sensor according to an embodiment for detecting pathogens in a sample, where the sensor includes a reference electrode to which an AC voltage can be applied,

FIG. 4A schematically depicts a functionalized graphene layer in which a plurality of linker molecules are employed for coupling antibodies to the graphene layer,

FIG. 4B schematically depicts the use of a passivation layer to cover the portions of the graphene layer that are not coupled to an antibody molecule,

FIG. 5 depicts a circuit diagram of an example of a voltage-measuring device that can be employed for measuring a voltage induced across an antibody-functionalized graphene layer in response to application of a current thereto,

FIG. 6A schematically depicts an analyzer in communication with the voltage-measuring device shown in FIG. 5 for receiving the voltage measured by the voltage-measuring device as well as the current applied to the antibody-functionalized graphene layer,

FIG. 6B depicts an example of implementation of the analyzer shown in FIG. 6A,

FIG. 7 schematically depicts a sensor according to an embodiment, which includes a plurality of sensing units configured to detect different types of pathogens,

FIG. 8 schematically depicts a microfluidic device that is coupled to the sensor shown in FIG. 7 for delivering a liquid sample thereto,

FIG. 9 schematically depicts a sensor according to an embodiment of the present teachings, which includes a plurality of sensing unit having graphene layers functionalized with different antibodies and a microfluidic device for introducing a sample onto the sensing units, and

FIG. 10 presents data indicative of detection of *Listeria* using an embodiment of the present teachings.

Detailed Description

It has been discovered that an anti-body functionalized graphene layer can be employed to detect the presence of pathogenic agents, such as *listeria monocytogene* bacterium (herein referred to as “*listeria*”) in a sample, for example, a food sample, a biological sample, such as urine and saliva. In particular, the interaction of a pathogen in a sample under investigation with the antibody-functionalized graphene layer can cause a change in at least one electrical property of the underlying graphene layer, e.g., a change in the electrical resistance of the underlying graphene layer. A detection of such a change in the electrical property of the underlying graphene layer can be employed to detect the presence of the pathogen in the sample under study. In some embodiments, the detection of a pathogen via an antibody-functionalized graphene layer can be facilitated via application of an AC signal to a reference electrode disposed in proximity of the graphene layer, e.g., positioned at a distance in a range of about 50 microns to about a few millimeter (e.g., 1-2 mm) from the graphene layer. By way of example, the frequency of the AC signal applied to the reference electrode can be in a range of about 1 kHz to about 1 MHz and the amplitude of the AC signal can be in a range of about 1 millivolt to about 3 volts.

Various terms are used herein in accordance with their ordinary meanings in the art. The term “about” as used herein to modify a numerical value is intended to denote a variation of at most 10% of the numerical value.

An “antibody”, as that term is used herein, refers to a polypeptide exhibiting specific binding affinity, e.g., an immunoglobulin chain or fragment thereof, comprising at least one functional immunoglobulin variable domain sequence. An antibody encompasses full length antibodies and antibody fragments. In some embodiments, an antibody comprises an antigen binding or functional fragment of a full length antibody, or a full length immunoglobulin chain. For example, a full-length antibody is an immunoglobulin (Ig) molecule (e.g., an IgG antibody) that is naturally occurring or formed by normal immunoglobulin gene fragment recombinatorial processes. In embodiments, an antibody refers to an immunologically active, antigen-binding portion of an immunoglobulin molecule, such as an antibody fragment. An antibody fragment, e.g., functional fragment, comprises a portion of an antibody, e.g., Fab,

Fab', F(ab')₂, F(ab)₂, variable fragment (Fv), domain antibody (dAb), or single chain variable fragment (scFv). A functional antibody fragment binds to the same antigen as that recognized by the intact (e.g., full-length) antibody.

The term “antibody” also encompasses whole or antigen binding fragments of domain, or single domain, antibodies, which can also be referred to as “sdAb” or “VHH.” Domain antibodies comprise either V_H or V_L that can act as stand-alone, antibody fragments. Additionally, domain antibodies include heavy-chain-only antibodies (HCAbs). Antibody molecules can be monospecific (e.g., monovalent or bivalent), bispecific (e.g., bivalent, trivalent, tetravalent, pentavalent, or hexavalent), trispecific (e.g., trivalent, tetravalent, pentavalent, hexavalent), or with higher orders of specificity (e.g. tetraspecific) and/or higher orders of valency beyond hexavalency. An antibody molecule can comprise a functional fragment of a light chain variable region and a functional fragment of a heavy chain variable region, or heavy and light chains may be fused together into a single polypeptide.

In many embodiments, an antibody is a glycoprotein produced by B lymphocytes in response to stimulation with an immunogen. An antibody can be composed of 4 polypeptides—2 heavy chains and 2 light chains—bound together by disulfide bonds to form a Y-shaped molecule.

FIGs. 1A and 1B schematically depict an example of a device 1000 according to an embodiment of the present teachings for detecting a pathogenic agent in a sample. The device 1000 includes a substrate 1002 on a top surface of which a layer of graphene 1004 is deposited. A variety of different substrates can be employed. By way of example, the substrate 1002 can be any of a semiconductor, such as silicon, or glass or plastic. In some embodiments in which the substrate 1002 is formed of silicon, a layer of silicon oxide can separate the upper graphene layer from the underlying silicon layer.

As shown schematically in FIG. 2, in this embodiment, the graphene layer 1004 is functionalized with an antibody 1004a that can specifically bind to a pathogen of interest. By way of example, in some embodiments, the graphene layer can be functionalized with listeria monocytogenes antibody LZ7 (BGN/0884/67), which is an IgG2a mouse anti-listeria monocytogenes monoclonal antibody. In another embodiment, the graphene layer can be functionalized with an anti-chlamydia antibody, such as monoclonal or polyclonal antibodies. A number of anti-chlamydia antibodies are commercially available. For example, anti-

chlamydia antibody marketed by Genetex under Cat#GTX40387 can be employed. In another embodiment, the graphene layer can be functionalized with anti-gonorrhea antibodies, e.g., monoclonal or polyclonal antibodies. For example, anti-gonorrhea antibody marketed by Creative Diagnostics under Cat#DMZB9759 can be employed. Yet, in another embodiment, the graphene layer can be functionalized with anti-HPV (human papilloma virus) antibodies. For example, anti-HPV antibody marketed by Abcam under Cat#ab2417 or by Thermo Fisher under Cat#MA512446 can be employed.

With reference to FIG. 4A, in some embodiments, the antibodies 1004a are coupled to the underlying graphene layer via a linker 4000, where the linker is covalently attached at one end thereof to the graphene layer. The antibodies can be attached to the other end of the linker, e.g., via a covalent bond. By way of example, in some embodiments, 1-pyrenebutonic acid succinimidyl ester can be employed as the linker to facilitate the coupling of the antibody molecules to the underlying graphene layer. It has been discovered that 1-pyrenebutonic acid succinimidyl ester can be used to couple a variety of different antibodies to the underlying graphene layer. As such, this linker can be used for coupling antibodies that specifically bind to a variety of different pathogens to the underlying graphene layer, where the pathogen-antibody interaction can mediate a change in one or more electrical properties of the underlying graphene layer.

In some embodiments, the graphene layer can be incubated with the linker molecule (e.g., a 5 mM solution of 1-pyrenebutonic acid succinimidyl ester) for a few hours (e.g., 2 hours) at room temperature to ensure covalently coupling of the linker molecules to the underlying graphene layer. The linker modified graphene layer can then be incubated with an antibody of interest in a buffer solution (e.g., NaCO_3 -- NaHCO_3 buffer solution (pH 9)) at a selected temperature and for a selected duration (e.g., 7-10 hours at 4 °C), followed by rinsing with deionized (DI) water and phosphate buffered solution (PBS). In order to quench the unreacted succinimidyl ester groups, the modified graphene layer can be incubated with ethanolamine (e.g., 0.1 M solution at a pH of 9 for 1 hour).

Subsequently, the non-functionalized areas of the graphene layer can be passivated via a passivation layer 1005, as shown in FIG. 4B. By way of example, the passivation of the non-functionalized portions of the graphene layer can be achieved, e.g., via incubation with 0.1% Tween 20 or BLOTTO, gelatin and/or amino-PEG5-alcohol (pH 7.4). Further details regarding the use of linkers for attaching antibody molecules to a graphene layer and

passivating the non-functionalized portions of the graphene layer can be found, e.g., in U.S. Patent No. 9,664,674 B2, which is herein incorporated by reference in its entirety.

Referring again to FIGs. 1A and 1B, two metallic pads 1005/1006 in electrical contact with the graphene layer 1004 allow measuring the electrical resistance of the graphene layer, and particularly, a change in the electrical resistance of the graphene layer in response to exposure thereof to a sample containing a pathogen, e.g., listeria, chlamydia, gonorrhea bacteria and/or HPV. In some embodiments, the electrically conductive pads can be formed of silver high conductive paste, though other electrically conductive materials can also be employed. The conductive pads can be electrically connected to a measurement device, e.g., a voltmeter, via a plurality of conductive wires for measuring the Ohmic electrical resistance of the graphene layer.

The device 1000 further includes a microfluidic structure 1008 having two reservoirs 1008a/1008b and a fluid channel 1008c that fluidly connects the two reservoirs. As shown more clearly in FIG. 1B, the fluid channel can be arranged such that a portion thereof is in fluid contact with a portion of the graphene layer 1004.

In some embodiments, in use, a sample suspected of containing a pathogen of interest, e.g., listeria bacteria, can be introduced into one of the reservoirs 1008a/1008b and can be made to flow, e.g., via application of hydrodynamic pressure thereto, to the other reservoir through the microfluidic channel 1008c. In this embodiment, a pump (such as pump 3010 depicted in the embodiment of FIG. 3) can be coupled to reservoir 1008b to facilitate the flow of the sample to the other reservoir. In other embodiments, the pump may be coupled to the other reservoir and/or to a fluid channel connecting those reservoirs. The passage of the sample through the channel 1008c brings the pathogen, if any, present in the sample into contact with the antibody-functionalized graphene layer 1004. Without being limited to any particular theory, the interaction of the pathogen, e.g., listeria bacteria with the antibodies to which they can bind can mediate a change in the electrical conductivity (and hence resistance) of the underlying graphene layer 1004, e.g., via charge transfer or other mechanisms. This change in the electrical conductivity of the graphene layer 1004 can in turn be measured to detect the presence of the pathogen in the sample under study.

In some embodiments, a four-point measurement technique can be used to measure the resistance of the antibody-functionalized graphene layer in response to exposure thereof to a sample under investigation.

By way of example, FIG. 5 schematically depicts a voltage measuring circuitry 701 that can be employed in some embodiments of the present teachings. This figure shows a sensor 702 as an equivalent circuit corresponding to an antibody-functionalized graphene layer. A fixed voltage V (e.g., 1.2 V) is generated at the output of a buffer operational amplifier 703. This voltage is applied to one input (A) of a downstream operational amplifier 704 whose other input B is coupled to VR1 ground via a resistor R1. The output of the operational amplifier 704 (V_{out1}) is coupled to one end of the sensor 702 and the end of the resistor R1 that is not connected to VR1 ground is coupled to the other end of the sensor 702 (in this schematic diagram, resistor R2 denotes the resistance between two electrode pads at one end of the equivalent sensor 702, resistor R3 denotes the resistance of the graphene layer extending between two inner electrodes of the sensor, and resistor R4 denotes the resistance between two electrode pads at the other end of the sensor). As the operational amplifier maintains the voltage at the end of the resistor R1 that is not connected to VR1 ground at the fixed voltage applied to its input (A), e.g., 1.2 V, a constant current source is generated that provides a constant current flow through the sensor 702 and returns to ground via the resistor R1 and VR1.

The voltage generated across the antibody-functionalized graphene layer is measured via the two inner electrodes of the sensor. Specifically, one pair of the inner electrode pads is coupled to a buffer operational amplifier 706 and the other pair is coupled to the other buffer operational amplifier 708. The outputs of the buffer operational amplifiers are applied to the input ports of a differential amplifier 710 whose output port provides the voltage difference across the antibody-functionalized graphene layer. This voltage difference ($V_{out1} - GLO$) can then be used to measure the resistance exhibited by the antibody-functionalized graphene layer. The current forced through R3 is set by $I = (V_{ref} - VR1)/R1$, where the value of VR1 is digitally controlled. For each value of current I , the corresponding voltage (V_{out1_GLO}) is measured and stored. The resistance of the antibody-functionalized graphene layer can be calculated as the derivative of the voltage, V_{out1_GLO} , with respect to current I , i.e., $R = dV/dI$.

As shown schematically in FIG. 6A, in some embodiments, an analyzer 600 can be in communication with the voltage measuring circuitry 701 to receive the applied current and the measured voltage value and use these values to calculate the resistance of the antibody-functionalized graphene layer. The analyzer can then employ the calculated resistance, e.g., a change in the resistance in response to exposure of the antibody-functionalized graphene layer to a sample under investigation, to determine, in accordance with the present teachings, whether the sample contains a pathogen of interest.

By way of example, as shown schematically in FIG. 6B, in this embodiment, the analyzer 600 can include a processor 602, an analysis module 604, a random access memory (RAM) 606, a permanent memory 608, a database 610, a communication module 612, and a graphical user interface (GUI) 614. The analyzer 600 can employ the communication module 612 to communicate with the voltage measuring circuitry 701 to receive the values of the applied current and the measured voltage. The communication module 612 can be a wired or a wireless communication module. The analyzer 600 further includes a graphical user interface (GUI) 614 that allows a user to interact with the analyzer 600.

The analysis module 604 can employ the values of a current applied to the antibody-functionalized graphene layer as well as the voltage induced across the graphene layer to calculate a change in the resistance of the antibody-functionalized graphene layer in response to exposure thereof to a sample under investigation. The instructions for such calculation can be stored in the permanent memory 608 and can be transferred at runtime to RAM 606 via processor 602 for use by the analysis module 604. In some embodiments, the database 610 can store calibration data that can be employed for determining whether a pathogen of interest is present in a sample under study. By way of example, the database 610 can store calibration data indicative of a temporal change in the electrical resistance of an antibody-functionalized graphene layer in response to exposure to a particular pathogen. A comparison of a measured temporal variation of a similar antibody-functionalized graphene exposed to a sample suspected of containing the pathogen with the calibrated response can be used to determine whether the pathogen is present in the sample. The GUI 614 can allow a user to interact with the analyzer 600.

Referring to FIG. 3, in some embodiments, the sensor 1000 according to an embodiment can include a reference electrode 3001 disposed in proximity of the antibody-functionalized graphene layer 1004, e.g., at a distance in a range of about 50 micrometers to

about a few millimeters (e.g., 1-2 millimeters) above the functionalized graphene layer. In some embodiments, the distance of the reference electrode relative to the functionalized graphene layer 1004 can be in a range of about 100 microns to about 1 millimeter, or in a range of about 200 microns to about 0.5 millimeter. Further, in some embodiments, rather than being positioned above the graphene layer, the reference electrode can be positioned in the same plane as the graphene layer.

The reference electrode can be utilized to generate a time-varying electric field at the interface of the functionalized graphene layer and a liquid sample, e.g., a liquid sample suspected of containing one or more pathogens, that is brought into contact with that layer. For example, in this embodiment, an AC voltage source 3002 can be employed to apply an AC voltage to the reference electrode, which can in turn result in the generation of a time-varying electric field in the space between the reference electrode and the functionalized graphene layer.

The AC reference electrode 3001 can be formed of any suitable electrical conductor. Some examples of suitable conductors include, without limitation, silver, copper, and gold. In some embodiments, the thickness of the reference electrode 3001 can be, for example, in a range of about 100 nm to about 400 micrometers (microns), e.g., in a range of about 1 microns to about 100 microns, though other thicknesses can also be employed.

The application of such a time-varying electric field via the reference electrode to the interface between the graphene layer 1004 and a liquid sample in contact with the graphene layer can advantageously facilitate the detection of one or more electrical properties of the antibody-functionalized graphene layer, e.g., a change in its resistance in response to its interaction with a pathogen present in the sample that exhibits specific binding to the antibody of the functionalized graphene layer. In particular, it has been discovered that the application of an AC voltage having a frequency in a range of about 1 kHz to about 1 MHz, e.g., in a range of about 10 kHz to about 500 kHz, or in a range of about 20 kHz to about 400 kHz, or in a range of about 30 kHz to about 300 kHz, or in a range of about 40 kHz to about 200 kHz, can be especially advantageous in this regard. By way of example, the amplitude of the AC voltage applied to the reference electrode can be in a range of about 1 millivolt to about 3 volts, e.g., in a range of about 100 millivolts to about 2 volts, or in range of about 200 millivolts to about 1 volt, or in range of about 300 millivolts to about 1 volt, e.g., in a range of about 0.5 volts to 1 volt. Further, in some cases, the voltage applied to the reference

electrode can have an AC component and a DC offset, where the DC offset can be in a range of about -40 volts to about +40 volts, e.g., -1 volt to about +1 volt.

Without being limited to any particular theory, in some embodiments, it is expected that the application of such a voltage to the reference electrode can minimize, and preferably eliminate, an effective capacitance associated with a sample, e.g., a liquid sample, with which the functionalized graphene layer is brought into contact as the sample is being tested, thereby facilitating the detection of a change in the resistance of the underlying graphene layer in response to the interaction of the antibodies with a respective pathogen. In some cases, the effective capacitance of the sample can be due to ions present in the sample.

The present teachings can be applied to detect a variety of pathogens, such as those discussed above, in a variety of different samples. Some examples of samples that can be interrogated include, without limitation, food samples and bodily fluids, such as blood, urine, saliva, etc.

In some embodiments, a sensor according to the present teachings is capable of detecting pathogens in a variety of different sample types including, without limitation, urine, mucous and/or blood. In some cases, e.g., when the detection of chlamydia is desired, the sample can be obtained by a swab, e.g., an endocervical swab. Other methods known in the art for obtaining samples can also be utilized.

With reference to FIG. 7, in some embodiments, a graphene-based sensor 800 according to the present teachings can include a plurality of sensing units 802a, 802b, 802c, and 802d, (herein collectively referred to as sensing units 802), each of which is configured for the detection of a different pathogen. In this embodiment, the sensing units 802 are formed on a single underlying substrate 804, e.g., a semiconductor (such as silicon), glass or plastic. Each sensing unit includes an antibody-functionalized graphene layer, fabricated in a manner discussed above. In this embodiment, at least two sensing units are functionalized with two different antibodies suitable for the detection of two different pathogens. For example, one sensing unit can be functionalized with an antibody that specifically binds to listeria bacterium and another sensing unit can be functionalized with an antibody that specifically binds to chlamydia bacterium. In some embodiments, each of the sensing units is functionalized with an antibody suitable for the detection of a different pathogen. By way of

example, the number of sensing units can range from 2 to 20, though other numbers can also be employed.

The sensing units 802 are electrically insulated from one another via an electrically insulating network 803. By way of example, the electrically-insulating network 803 can be in the form of a plurality of electrically-insulating strips formed, e.g., of silicon oxide (such as SiO_2), which can electrically isolate different sensing units from one another. Further, in this embodiment, each of the sensing units 800 includes a reference electrode 806a, 806b, 806c, and 806d (herein referred to collectively as reference electrodes 806) to which AC signals can be applied, e.g., in a manner discussed above, to facilitate the detection of a pathogen of interest. While in some embodiments, the frequency and amplitude of the AC signal applied to the different sensing units can be the same, in other embodiments, the AC signals applied to at least two different sensing units can exhibit different frequencies and/or amplitudes.

In some embodiments, rather than employing multiple reference electrodes, a single reference electrode can be employed for applying a reference AC voltage to multiple, or all, of the sensing units 802. The frequency and the amplitude of the applied reference AC voltage can be, for example, in the ranges discussed above.

With continued reference to FIG. 7, a voltage measuring device 808 can be employed to measure a voltage across each of the sensing units in response to application of a predefined constant current thereto, e.g., in a manner discussed above in connection with the voltage measuring device 701. In this embodiment, a multiplexer 810 can be employed to selectively measure the voltage induced across the sensing units in response to application of a predefined current thereto, e.g., in a time-wise sequential manner. An analyzer 812, such as the above analyzer 600, can receive the voltage data from the voltage measuring device 808 and can calculate the change in the electrical resistance of the underlying graphene layer to determine whether one or more of the pathogens are present in the sample under study.

With reference to FIG. 8, in some embodiments, a microfluidic device 900 can be fluidly coupled to the sensor 800 for delivering a liquid sample suspected of containing one or more pathogens of interest to the sensor 800. In this embodiment, the microfluidic device 900 includes a body 902 having an input port 903 for receiving a sample. Each of a plurality of internal channels 904a, 904b, 904c, 904d and 904e (herein collectively referred to as channels 904) in fluid communication with the input port 903 can receive a portion of the

sample via the input port 903 and guide those portions to output ports 906a, 906b, 906c, and 906d (herein collectively referred to as output ports 906), which in turn deliver those sample portions to the sensing units for analysis.

FIG. 9 schematically depicts another embodiment of a sensor 1000 according to the present teachings, which includes sensing units 1002, 1004, and 1006 are disposed. Each of the sensing units 1002, 1004, and 1006 includes a graphene layer that is functionalized with an antibody that exhibits specific binding for a different pathogen, in a manner discussed above. In this embodiment, the graphene layers of the sensing units 1002, 1004, and 1006 are deposited on the top surface of a single underlying substrate 1007, e.g., a silicon substrate. In this embodiment, the sensing units are separated from one another by a plurality of electrically insulating strips 1009, which can be formed, e.g., from silicon oxide.

With continued reference to FIG. 9, in this embodiment, a microfluidic device 1010 is coupled to the sensing units 1002, 1004, and 1006 for delivering a sample under investigation to the sensing units. In this embodiment, the microfluidic device 1010 includes three fluidic channels 1011, 1013, and 1015, e.g., each of which has a diameter in a range of about 10 microns to about 100 microns and is in fluid communication with the antibody-functionalized graphene layer of one of the sensing units. The channels 1011, 1013, and 1015 are fluidically coupled via an input manifold 1017 to an input port 1019 through which a sample can be introduced into the microfluidic device 1010. The input manifold 1017 can distribute a portion of the received sample to each of the channels 1011, 1013 and 1015. The channels 1011, 1013 and 1015 terminate in an return manifold 1020 that is in turn fluidly coupled to a return channel 1021, which can direct the fluid back to the input manifold, thereby providing closed-loop fluid circulation. A input pump 1022, e.g., a gear pump, can facilitate the flow of the sample into the input manifold, and a return pump 1024 can facilitate the return of the fluid exiting the channels 1011, 1013, and 1015 back to the input manifold 1017.

In some embodiments, rather than employing a single return microfluidic channel, a plurality of return microfluidic channels, each associated with one of the sensing units, can be employed.

Similar to the previous embodiment, a change of the electrical resistance of the antibody-functionalized graphene layer of each sensing unit can be measured and correlated with the presence of a particular pathogen for which that sensing unit is configured.

Although in the above embodiments, the resistance of the antibody-functionalized graphene layer is measured via application of a predefined current to the graphene layer following by measuring a voltage induced across the graphene layer, in other embodiments, a predefined voltage can be applied across the graphene layer and a current flow through the graphene layer caused by the applied voltage can be measured. The values of the voltage and current can then be employed, for example, in a manner discussed above, to arrive at the resistance of the graphene layer (e.g., using Ohm's law).

A sensor according to the present teachings can be employed in a variety of settings. By way of example, a sensor according to the present teachings can be employed in a medical setting. Further, a sensor according to the present teachings can be employed for home use. In such cases, the analyzer can be implemented on a mobile device. In addition or alternatively, the analyzer can be implemented on a remote server that can be in communication with the sensor via a network, e.g., the Internet, to receive sensing data, such as a voltage measured across the antibody-functionalized graphene layer. The analyzer can employ the sensing data to determine whether a pathogen of interest is present in a sample under study in a manner discussed above.

The following example is provided for further elucidation of various aspects of the invention and is not intended to provide necessarily the optimal way of practicing the present teachings or optical results that can be obtained.

Example

A microfluidic chip based on the design depicted in FIGs. 1A and 1B was fabricated. The conductive pads were formed of Silver high conductive paste purchased from MG Chemicals of Canada. The high conductive paste was employed to electrically connect the graphene layer to a measurement circuit for detecting the electrical response of the graphene layer to a test sample containing heat-killed *Listeria monocytogenes*.

The graphene layer was functionalized with *Listeria monocytogenes* Antibody LZF7 (BGN/0884/67), which is an IgG2a Mouse anti *Listeria monocytogenes* Monoclonal Antibody and was purchased from Bio-Rad. The functionalization process included covalently attaching a plurality of linker molecules to the graphene layer at one end thereof and coupling the antibody molecules to the other end of the linker molecules. In this example, the linker molecule was 1-pyrenebutonic acid succinimidyl ester. The procedures

for attaching the linker molecules to the graphene layer and coupling antibody molecules to the linker molecules described in U.S. Patent No. 9,664,674 B2, which is herein incorporated by reference in its entirety, were followed.

A freeze-dried heat-killed preparation of *Listeria monocytogenes* (HKLM) was purchased from InvivoGen of San Diego, CA. After mixing the listeria preparation with endotoxin-free water, 1 mL of the resultant solution contained 10^7 to 10^8 bacteria. The bacteria were then stained by 5% violet crystal solution purchased from Sigma-Aldrich and washed 4 times by deionized (DI) water to remove the excessive dyes in the solution. Then, in two steps, the solution was diluted to 10^4 to 10^3 bacteria per mL.

Subsequently, 1 mL of the sample was mixed with 9 mL of the Phosphate-buffered saline (PBS) buffer to achieve a concentration of 10^3 to 10^2 bacteria per mL. The sample was then injected into the chip by using a syringe pump at the rate of 1 mL/hour for two hours (phase 1). Then the syringe was disconnected and blank PBS buffer solution was pumped in to the chip for another two hours (Phase 2). Then the vial was disconnected and *Listeria* sample again was injected into the chip for another 2 hours.

The electrical resistance of the graphene was monitored using a four-probe based circuit such that the one described in the aforementioned U.S. Patent No. 9,664,674 and data was recorded on the connected computer. The results are shown in the graph presented in FIG. 10. The data shows that the resistance of the graphene layer decreases during phase 1 as the bacterial cells interact with the antibody-functionalized graphene layer. During phase 2, no change in the resistance of the graphene layer is observed. This shows that the change in the resistance of the graphene layer observed during phase 1 can be attributed to the interaction of the listeria bacteria with the antibody-functionalized graphene. As the sample containing bacterial cells is reintroduced into the chip during phase 3, the resistance of the graphene layer begins to decrease again, albeit at a smaller slope relative to the change of resistance observed during phase 1. Without being limited to any particular theory, the smaller slope observed during phase 2 may be due to a lower number of available sites on the antibody-functionalized graphene with which the listeria bacteria can interact.

The above data clearly shows that the detection of listeria bacteria, even at small concentrations, is feasible by using the present teachings.

Those having ordinary skill in the art will appreciate that various changes can be made to the above embodiments without departing from the scope of the invention.

Claims

1. A method of detecting a pathogenic agent in a sample, comprising:
bringing a sample into contact with a graphene layer functionalized with an antibody exhibiting specific binding affinity to said pathogenic agent,
applying a time-varying electric field to said antibody-functionalized graphene layer, monitoring electrical resistance of said graphene layer in response to interaction with said sample, and
detecting presence of said pathogenic agent in said sample by detecting a change in said electrical resistance indicative of interaction of said pathogenic agent with said antibody-functionalized graphene layer.
2. The method of claim 1, wherein said time-varying electric field has a frequency in a range of about 1 kHz to about 1 MHz.
3. The method of claim 1, wherein said graphene layer is disposed on an underlying substrate.
4. The method of claim 3, wherein said substrate is any of semiconductor and glass.
5. The method of claim 3, wherein a microfluidic structure is coupled to said semiconductor substrate, said microfluidic structure having at least one reservoir and a fluidic channel fluidly coupled to said reservoir, said fluid channel being in fluid communication with at least a portion of said graphene layer, and said reservoir being configured for receiving a sample.
6. The method of claim 5, wherein said graphene layer is electrically coupled to a pair of conductive pads for facilitating measurement of an electrical resistance of said graphene layer in response to interaction with said sample.
7. The method of claim 1, wherein said pathogenic agent comprises listeria bacteria.
8. The method of claim 1, wherein said pathogenic agent comprises chlamydia bacteria.
9. The method of claim 1, wherein said pathogenic agent comprises gonorrhea bacteria.
10. The method of claim 1, wherein said pathogenic agent comprises HPV.

11. A sensor for detecting a pathogen in sample, comprising
a substrate,
a graphene layer deposited on a surface of said substrate, said graphene layer being functionalized with a plurality of antibodies exhibiting specific binding affinity to said pathogen,
a microfluidic delivery device coupled to said functionalized graphene layer for delivery of a fluid sample thereto,
wherein said microfluidic device comprises
two fluid reservoirs and a fluid channel connecting said two reservoirs,
wherein said fluid channel is configured such that at least a portion thereof is in fluid contact with at least a portion of the graphene layer.
12. The sensor of claim 11, further comprising a reference electrode disposed in proximity of said antibody-functionalized graphene layer.
13. The sensor of claim 11, further comprising an AC voltage source for applying an AC voltage to said reference electrode.
14. The sensor of claim 13, wherein said AC voltage source is configured to apply an AC voltage having a frequency in a range of about 1 kHz to about 1 MHz.
15. The sensor of claim 14, wherein said AC voltage has an amplitude in a range of about 1 millivolts to about 3 volts.
16. A system for detecting pathogenic agents, comprising:
a sensor configured for detecting at least two pathogenic agents, said sensor comprising:
a substrate,
a plurality of sensing units disposed on said substrate, each of said sensing units comprising an antibody-functionalized graphene layer disposed on said substrate,
wherein at least two of said sensing units comprise antibodies configured for specific binding to at least two different pathogens.
17. The system of claim 16, further comprising at least one reference electrode for applying an AC signal to at least one of said sensing units.

18. The system of claim 17, wherein the AC signal has a frequency in a range of about 1 kHz to about 1 MHz.
19. The system of claim 18, wherein the AC signal has an amplitude in a range of about 1 mV to about 3 V.
20. The system of claim 17, wherein said at least one reference electrode comprises a plurality of reference electrodes each of which is configured for application of an AC signal to one of said sensing units.
21. The system of claim 16, further comprising at least one voltage measuring device for measuring a voltage developed across one or more of said sensing units in response to application of a predefined current thereto.
22. The system of claim 19, further comprising an analyzer in communication with said voltage measuring device for receiving said measured voltage and said predefined current and calculating a change in electrical resistance of said antibody-functionalized graphene layer in response to exposure to a sample.

FIG. 1A




FIG. 1B




FIG. 2




FIG. 3

■




FIG. 4A




FIG. 4B

6/12




FIG. 5

7/12




FIG. 6A

8/12




FIG. 6B

9/12




FIG. 7




FIG. 8




FIG. 9




FIG. 10

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 19/15579

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - C12M 1/34, C12Q 1/00, B01L 3/00, G01N 33/53, G01N 33/543 (2019.01)

CPC - G01N 27/02, G01N 33/53, G01N 33/544, G01N 1/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

See Search History Document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

See Search History Document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

See Search History Document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X ----- Y	US 2016/0223538 A1 (MCALPINE et al.) 4 August 2016 (04.08.2016); para [0008], [0010], [0012], [0035], [0065], [0067], [0104], [0108], [0121], [0136], [0143]	1-7 ----- 8-10
Y	WO 2017/103269 A1 (SELFDIAGNOSTICS DEUTSCHLAND GMBH) 22 June 2017 (22.06.2017); abstract; pg 1, ln 7-11; pg 1, ln 13-16; pg 4, ln 21-25	8-10

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

28 May 2019

Date of mailing of the international search report

18 JUN 2019

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-8300

Authorized officer:

Lee W. Young

PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 19/15579

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1-10, directed to a method of detecting a pathogenic agent in a sample.

Group II, claims 11-22, directed to a sensor for detecting a pathogen in sample, and a system comprising the sensor.

The inventions listed as Groups I-II do not relate to a single special technical feature under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Special technical features:

*****Continued in Supplemental Box*****

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-10

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

Continuation of Box No: III (Observations where unity of invention is lacking):

Group I has the special technical feature of contacting a sample with a graphene layer functionalized with an antibody, applying an electric field, monitoring electrical resistance, and detecting presence of a pathogenic agent, that is not required by Group II.

Group II has the special technical feature of a sensor comprising a substrate and a microfluidic delivery device, that is not required by Group I.

Common technical features:

Groups I-II share the common technical feature of a graphene layer functionalized with an antibody exhibiting specific binding affinity to said pathogenic agent for sensing/detection of a pathogen in sample. However, this shared technical feature does not represent a contribution over prior art, because this shared technical feature is taught by US 2016/0223538 A1 to McAlpine et al. (hereinafter "McAlpine").

McAlpine teaches a method of detecting a pathogenic agent in a sample (abstract "A biosensor and method of making are disclosed. The biosensor is configured to detect a target and may include a peptide immobilized on a sensing component, the sensing component having an anode and a cathode...The immobilized peptide may bind one or more targets selected from the list consisting of: bacteria, Gram-negative bacteria, Gram-positive bacteria, pathogens, protozoa, fungi, viruses, and cancerous cells"), comprising: bringing a sample into contact with a graphene layer functionalized with an antibody exhibiting specific binding affinity to said pathogenic agent (para [0008] "The sensing component may be a graphene substrate."; [0012] "The biosensor may include an interdigitated microelectrode array disposed on a bioresorbable substrate...A binding molecule may be disposed on the interdigitated microelectrode array...The binding molecule may be selected from the list consisting of... antibodies"), applying a time-varying electric field to said antibody-functionalized graphene layer, monitoring electrical resistance of said graphene layer in response to interaction with said sample, and detecting presence of said pathogenic agent in said sample by detecting a change in said electrical resistance indicative of interaction of said pathogenic agent with said antibody-functionalized graphene layer (para [0136] " Upon the recognition and binding of specific bacterial targets by the immobilized antimicrobial peptides (FIG. 11D), the electrical conductivity of the graphene film changes, which can be wirelessly monitored"; [0143] "To demonstrate the response of the graphene-nanosensors towards single bacterial cells and to characterize the sensitivity of the graphene transducing element, simultaneous electrical and optical measurements were conducted. Time dependent resistance data recorded simultaneously with optical measurements on graphene nanosensors showed discrete changes in the graphene resistance in the presence of a sample of approximately 100 bacterial cells per uL loaded on to the sensor elements by pipette (see FIG. 13A). Simultaneous collection of electrical and fluorescence data from the graphene sensors in the presence of fluorescently labeled "E. coli" cells clearly indicate that the change in the resistance recorded corresponds to the binding and unbinding of the bacterial cell from the graphene surface"; [0155] "This particular embodiment is not limited to combination with antimicrobial peptides, but can be used with an detection molecule capable of creating a variance in impedance including but not limited to antibodies").

As the technical features were known in the art at the time of the invention, they cannot be considered special technical features that would otherwise unify the groups.

Therefore, Group I-II inventions lack unity under PCT Rule 13 because they do not share the same or corresponding special technical feature.